Bevacizumab
Bevacizumab (trade name Avastin) is a recombinant humanized monoclonal IgG1 antibody used as an anti-angiogenic therapy, chiefly in oncology.
Bevacizumab (trade name Avastin) is a recombinant humanized monoclonal IgG1 antibody used as an anti-angiogenic therapy, chiefly in oncology. It binds vascular endothelial growth factor A (VEGFA) with high affinity and prevents it from engaging its receptors VEGFR-1 and VEGFR-2, blocking the signaling that drives new vessel formation in tumors. Because it neutralizes the ligand in the extracellular space, its mechanism differs from that of small-molecule tyrosine kinase inhibitors such as sorafenib, lenvatinib or cabozantinib, which act on receptor kinase domains inside the cell — a distinction that matters for toxicity, since the antibody hits one ligand while the kinase inhibitors hit many targets at once. Approved in 2004, it is given intravenously, generally in combination, across colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, ovarian cancer and cervical cancer, paired with cytotoxic backbones such as irinotecan, carboplatin and paclitaxel, or cisplatin plus paclitaxel; in cervical cancer the alternative backbone is topotecan plus paclitaxel rather than fluorouracil-containing regimens. Anti-VEGF agents of this class, including Ranibizumab and aflibercept, are also given intravitreally in retinal vascular disease, where bevacizumab itself is widely used off-label at a fraction of the cost.
Beyond suppressing angiogenesis, VEGFA blockade remodels the tumor microenvironment. Vascular normalization can improve perfusion and drug delivery, while reduced VEGF signaling lessens the immunosuppression VEGF exerts on dendritic cells, regulatory T cells and myeloid populations — the rationale for combining it with checkpoint inhibitors. The combination with the CD274 molecule antibody atezolizumab is now first-line standard of care for unresectable hepatocellular carcinoma, and analogous immunotherapy-plus-antiangiogenic strategies are under study with pembrolizumab and durvalumab.
The toxicities follow from blocking a pathway that healthy tissue also uses: hypertension and proteinuria from effects on endothelium and glomerulus, impaired wound healing that requires surgery to be spaced around dosing, arterial and venous thrombosis, bleeding — of particular concern in cirrhotic patients with portal hypertension — and, uncommonly but seriously, gastrointestinal perforation. Combined immune-targeted regimens add immune-related toxicities on top of these. Bevacizumab's capacity to reduce vascular permeability and edema has also prompted non-oncologic use, for instance in radiation-induced tissue injury.
Where the papers sit
37 papers from the last 6 months study bevacizumab directly · updated from PubMed 16 Nov 2026
Study type 2 clinical trials · 21 observational · 7 human data · 2 preclinical · 5 unclassified
Themes one subject · 1 paradigm shift · 1 new direction
Those 37 are all about one subject.
-
Antiangiogenic Cancer Therapy
Antiangiogenic therapy is used across metastatic colorectal cancer and hepatocellular carcinoma, with bevacizumab paired with chemotherapy or immune checkpoint blockade. Refractory colorectal disease is shifting toward trifluridine–tipiracil, liposomal irinotecan, capecitabine, and regorafenib combinations, while HCC studies emphasize AFP/LMR dynamics and cardiovascular risk. Safety monitoring recurs around hypertension, proteinuria, thrombotic microangiopathy, perforation, pulmonary artery enlargement, and hepatic complications; SGLT2 inhibitors and risk scores are being explored for mitigation. Other work covers radiation necrosis, respiratory papillomatosis, dosing, biosimilar value, and imaging prediction, leaving efficacy comparisons and patient selection open.
Atezolizumab–bevacizumab should not be treated as a uniformly preferred first-line regimen in unresectable hepatocellular carcinoma
The baseline-DCP biomarker study in unresectable hepatocellular carcinoma and the response-pattern study comparing durvalumab plus tremelimumab with atezolizumab plus bevacizumab both challenge the assumption that atezolizumab–bevacizumab is an interchangeable first-line choice for all patients. The former found that baseline DCP modified objective response according to regimen, while the latter observed a higher objective response rate with durvalumab–tremelimumab than with atezolizumab–bevacizumab, although its analysis was descriptive and hypothesis-generating 42477505Jul 42674706Aug. The result is a shift toward biomarker- and response-pattern-guided selection of first-line therapy rather than treating bevacizumab-containing immunotherapy as uniformly preferable.
Bevacizumab is used as a formulation analyte for measuring therapeutic-protein oligomerization
The therapeutic-protein formulation study on hydrodynamic molecular-weight measurement used bevacizumab, alongside other biologics, as a formulation sample rather than as an anticancer treatment. Its diffusion-based model produced hydrodynamic molecular weights several-fold above bevacizumab’s monomeric molecular weight, indicating oligomerization and extending bevacizumab’s role to the physical characterization of drug-product structure and stability 42373916Jun.
Papers
The 37 papers from the last 6 months that study bevacizumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Antiangiogenic Cancer Therapy (37)
- Adverse event signals associated with targeted therapy plus chemotherapy in colorectal cancer: A FAERS-based pharmacovigilance study. Medicine · 6 Nov 2026 PMID 42994833
- Resolution of Severe Jaundice Following Hepatic Artery Infusion of Bevacizumab and 5-Fluorouracil With Oral Regorafenib in Metastatic Colorectal Cancer:A Case Report. The American journal of case reports · 4 Nov 2026 PMID 42981239
- Liposomal irinotecan and capecitabine plus bevacizumab as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm study. Cancer · 1 Nov 2026 PMID 42967221
- Uncovering the full economic impact of biosimilars: a "would have spent" counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016-2025. Journal of medical economics · 28 Oct 2026 PMID 42948929
- 14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan. Lancet (London, England) · 24 Oct 2026 PMID 42925880
- Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092). Future oncology (London, England) · 21 Oct 2026 PMID 42902603
- Comparative dosing of bevacizumab for radiation necrosis: impact of tumor type on edema response. Journal of neuro-oncology · 10 Oct 2026 PMID 42859298
- Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores. Liver international : official journal of the International Association for the Study of the Liver · 7 Oct 2026 PMID 42839680
- Juvenile recurrent respiratory papillomatosis treated with systemic bevacizumab: A single-center pediatric case series. International journal of pediatric otorhinolaryngology · 23 Sept 2026 PMID 42777554
- Main pulmonary artery enlargement during bevacizumab therapy in KRAS-mutant metastatic colon cancer. Cancer chemotherapy and pharmacology · 17 Sept 2026 PMID 42752894
- Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab. Journal of neuro-oncology · 10 Sept 2026 PMID 42717134
- Gastrointestinal perforation associated with bevacizumab and palliative radiotherapy. International journal of clinical oncology · 6 Sept 2026 PMID 42701139
- Biopsy-proven kidney-limited thrombotic microangiopathy associated with bevacizumab and pegylated liposomal doxorubicin: a case with a biphasic clinical course. CEN case reports · 2 Sept 2026 PMID 42684642
- Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674726
- Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Anticancer research · 31 Aug 2026 PMID 42674706
- Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674689
- The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer: Aretrospective single-arm study. Taiwanese journal of obstetrics & gynecology · 25 Aug 2026 PMID 42642147
- Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
- Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy. Clinical nutrition ESPEN · 20 Aug 2026 PMID 42624401
- Postoperative cutaneous metastasis of breast cancer with phenotypic conversion to triple-negative subtype: A case report. Medicine · 15 Aug 2026 PMID 42601691
- Relative Dose Intensity and Clinical Outcomes of Using Trifluridine/Tipiracil with or without Bevacizumab in Patients Aged ≥ 75 Years with Advanced or Recurrent Colorectal Cancer: a Single-Center Retrospective Study. Journal of gastrointestinal cancer · 14 Aug 2026 PMID 42599544
- Cost-effectiveness of finotonlimab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in China. Human vaccines & immunotherapeutics · 27 Jul 2026 PMID 42505057
- Efficacy and prognostic factors of first-line bevacizumab plus chemotherapy in elderly patients with advanced driver gene-negative lung adenocarcinoma: A retrospective study. Medicine · 25 Jul 2026 PMID 42499069
- Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a multicentre UK Midlands cohort. BMC cancer · 20 Jul 2026 PMID 42477572
- Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC. Liver international : official journal of the International Association for the Study of the Liver · 20 Jul 2026 PMID 42477505
- Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World. Journal of gastrointestinal cancer · 16 Jul 2026 PMID 42461453
- Machine learning algorithms develop a tumor-educated platelets-related gene signature to predict colorectal cancer prognosis and therapy response. iScience · 30 Jun 2026 PMID 42375537
- Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. The AAPS journal · 29 Jun 2026 PMID 42373916
- Balloon-occluded Alternative Infusion of Fragmented Gelatin Particles of TACE for Hepatocellular Carcinoma Refractory to Atezolizumab-Bevacizumab. Anticancer research · 29 Jun 2026 PMID 42373279
- Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial. The lancet. Gastroenterology & hepatology · 22 Jun 2026 PMID 42330996
- Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers. International journal of clinical oncology · 15 Jun 2026 PMID 42298055
- Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort. JHEP reports : innovation in hepatology · 11 Jun 2026 PMID 42276189
- Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study. International journal of cancer · 11 Jun 2026 PMID 42272324
- Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis. Oncology · 29 May 2026 PMID 42213615
- Bevacizumab for Radiation-Induced (Radiculo)plexopathy. European journal of neurology · 28 May 2026 PMID 42206990
- Ameliorative effects of bevacizumab against sepsis-induced acute kidney injury: investigation of inflammatory responses, pyroptosis-related signalling and angiogenesis in a murine model of polymicrobial sepsis. Molecular biology reports · 27 May 2026 PMID 42201618
- Chemoport-related right innominate vein stenosis in patients with colorectal cancer: A retrospective risk factor analysis. PloS one · 20 May 2026 PMID 42160312
By study type
Clinical trials (2)
- 14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan. Lancet (London, England) · 24 Oct 2026 PMID 42925880
- Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial. The lancet. Gastroenterology & hepatology · 22 Jun 2026 PMID 42330996
Observational studies and case reports (21)
- Resolution of Severe Jaundice Following Hepatic Artery Infusion of Bevacizumab and 5-Fluorouracil With Oral Regorafenib in Metastatic Colorectal Cancer:A Case Report. The American journal of case reports · 4 Nov 2026 PMID 42981239
- Comparative dosing of bevacizumab for radiation necrosis: impact of tumor type on edema response. Journal of neuro-oncology · 10 Oct 2026 PMID 42859298
- Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores. Liver international : official journal of the International Association for the Study of the Liver · 7 Oct 2026 PMID 42839680
- Juvenile recurrent respiratory papillomatosis treated with systemic bevacizumab: A single-center pediatric case series. International journal of pediatric otorhinolaryngology · 23 Sept 2026 PMID 42777554
- Main pulmonary artery enlargement during bevacizumab therapy in KRAS-mutant metastatic colon cancer. Cancer chemotherapy and pharmacology · 17 Sept 2026 PMID 42752894
- Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab. Journal of neuro-oncology · 10 Sept 2026 PMID 42717134
- Gastrointestinal perforation associated with bevacizumab and palliative radiotherapy. International journal of clinical oncology · 6 Sept 2026 PMID 42701139
- Biopsy-proven kidney-limited thrombotic microangiopathy associated with bevacizumab and pegylated liposomal doxorubicin: a case with a biphasic clinical course. CEN case reports · 2 Sept 2026 PMID 42684642
- Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674726
- Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Anticancer research · 31 Aug 2026 PMID 42674706
- Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674689
- The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer: Aretrospective single-arm study. Taiwanese journal of obstetrics & gynecology · 25 Aug 2026 PMID 42642147
- Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy. Clinical nutrition ESPEN · 20 Aug 2026 PMID 42624401
- Postoperative cutaneous metastasis of breast cancer with phenotypic conversion to triple-negative subtype: A case report. Medicine · 15 Aug 2026 PMID 42601691
- Relative Dose Intensity and Clinical Outcomes of Using Trifluridine/Tipiracil with or without Bevacizumab in Patients Aged ≥ 75 Years with Advanced or Recurrent Colorectal Cancer: a Single-Center Retrospective Study. Journal of gastrointestinal cancer · 14 Aug 2026 PMID 42599544
- Efficacy and prognostic factors of first-line bevacizumab plus chemotherapy in elderly patients with advanced driver gene-negative lung adenocarcinoma: A retrospective study. Medicine · 25 Jul 2026 PMID 42499069
- Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC. Liver international : official journal of the International Association for the Study of the Liver · 20 Jul 2026 PMID 42477505
- Balloon-occluded Alternative Infusion of Fragmented Gelatin Particles of TACE for Hepatocellular Carcinoma Refractory to Atezolizumab-Bevacizumab. Anticancer research · 29 Jun 2026 PMID 42373279
- Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study. International journal of cancer · 11 Jun 2026 PMID 42272324
- Bevacizumab for Radiation-Induced (Radiculo)plexopathy. European journal of neurology · 28 May 2026 PMID 42206990
- Chemoport-related right innominate vein stenosis in patients with colorectal cancer: A retrospective risk factor analysis. PloS one · 20 May 2026 PMID 42160312
Human data, design not indexed (7)
- Adverse event signals associated with targeted therapy plus chemotherapy in colorectal cancer: A FAERS-based pharmacovigilance study. Medicine · 6 Nov 2026 PMID 42994833
- Liposomal irinotecan and capecitabine plus bevacizumab as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm study. Cancer · 1 Nov 2026 PMID 42967221
- Uncovering the full economic impact of biosimilars: a "would have spent" counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016-2025. Journal of medical economics · 28 Oct 2026 PMID 42948929
- Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
- Cost-effectiveness of finotonlimab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in China. Human vaccines & immunotherapeutics · 27 Jul 2026 PMID 42505057
- Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World. Journal of gastrointestinal cancer · 16 Jul 2026 PMID 42461453
- Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers. International journal of clinical oncology · 15 Jun 2026 PMID 42298055
Preclinical: animal, cell and lab studies (2)
- Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. The AAPS journal · 29 Jun 2026 PMID 42373916
- Ameliorative effects of bevacizumab against sepsis-induced acute kidney injury: investigation of inflammatory responses, pyroptosis-related signalling and angiogenesis in a murine model of polymicrobial sepsis. Molecular biology reports · 27 May 2026 PMID 42201618
Unclassified: not yet indexed with MeSH (5)
- Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092). Future oncology (London, England) · 21 Oct 2026 PMID 42902603
- Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a multicentre UK Midlands cohort. BMC cancer · 20 Jul 2026 PMID 42477572
- Machine learning algorithms develop a tumor-educated platelets-related gene signature to predict colorectal cancer prognosis and therapy response. iScience · 30 Jun 2026 PMID 42375537
- Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort. JHEP reports : innovation in hepatology · 11 Jun 2026 PMID 42276189
- Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis. Oncology · 29 May 2026 PMID 42213615
Written from 37 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-19 by GPT. Corrections: 2026-08-08 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.